GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NovelStem International Corp (OTCPK:NSTM) » Definitions » Intrinsic Value: Projected FCF

NovelStem International (NovelStem International) Intrinsic Value: Projected FCF : $-0.29 (As of Jun. 07, 2024)


View and export this data going back to 1995. Start your Free Trial

What is NovelStem International Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-07), NovelStem International's Intrinsic Value: Projected FCF is $-0.29. The stock price of NovelStem International is $0.0601. Therefore, NovelStem International's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for NovelStem International's Intrinsic Value: Projected FCF or its related term are showing as below:

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of NovelStem International was 22.49. The lowest was 22.49. And the median was 22.49.

NSTM's Price-to-Projected-FCF is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.625
* Ranked among companies with meaningful Price-to-Projected-FCF only.

NovelStem International Intrinsic Value: Projected FCF Historical Data

The historical data trend for NovelStem International's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovelStem International Intrinsic Value: Projected FCF Chart

NovelStem International Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.70 -0.36 -0.33 -0.06 -0.28

NovelStem International Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.01 -0.05 -0.28 -0.29

Competitive Comparison of NovelStem International's Intrinsic Value: Projected FCF

For the Diagnostics & Research subindustry, NovelStem International's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovelStem International's Price-to-Projected-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NovelStem International's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where NovelStem International's Price-to-Projected-FCF falls into.



NovelStem International Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get NovelStem International's Free Cash Flow(6 year avg) = $-1.12.

NovelStem International's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Mar24)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-1.11648+-2.241/0.8)/46.881
=-0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovelStem International  (OTCPK:NSTM) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

NovelStem International's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0601/-0.28648134958433
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovelStem International Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of NovelStem International's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


NovelStem International (NovelStem International) Business Description

Traded in Other Exchanges
N/A
Address
2255 Glades Road, Suite 221A, Boca Raton, FL, USA, 33431
NovelStem International Corp owns novel stem-cell-based diagnostic technology for predicting patients' resistance to cancer therapies. The technology is also being used for genetic research related to other medical therapies.
Executives
Baker Street Capital Management, Llc 10 percent owner 1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Vadim Perelman 10 percent owner 1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Baker Street Capital L.p. 10 percent owner 1875 CENTURY PARK EAST, SUITE 700, LOS ANGELES CA 90067
Stephen Gans director, 10 percent owner 14850 NW 44TH COURT, OPA LOCKA FL 33054
Shannon River Partners Lp 10 percent owner 850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Shannon River Fund Management Co Llc 10 percent owner 850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Shannon River Partners Ii, Lp 10 percent owner 850 THIRD AVENUE, 13TH FLOOR, NEW YORK NY 10022
Doonbeg Fund Lp 10 percent owner 850 THIRD AVE, 13TH FLOOR, New York ny 10022
Spencer M. Waxman director C/O SHANNON RIVER PARTNERS, 800 THIRD AVENUE 30TH FLOOR, NEW YORK NY 10022
Stanley Morgan 10 percent owner 1585 BROADWAY, NEW YORK NY 10036
Robert D. Epstein director 2255 GLADES ROAD, BOCA RATON FL 33431
Coghill Capital Management Llc 10 percent owner 233 SOUTH WACKER DRIVE, SUITE 8439, CHICAGO IL 60606
Ccm Master Fund Ltd 10 percent owner C/O MORGAN STANLEY FUND SERVICES (CAYMAN, LTD CENTURY YARD CRICKET SQ HUTCHINGS DR, PO BOX 2681 GEORGE TOWN E9 00000
Clint D Coghill 10 percent owner
Scott Gomez officer: Chief Accounting Officer

NovelStem International (NovelStem International) Headlines

From GuruFocus

NewStem Announces $4 million Seed Investment

By PRNewswire PRNewswire 07-16-2018